Last reviewed · How we verify
Camoform (BIALAMICOL)
Camoform (generic name: BIALAMICOL) is a drug. It is currently in Phase 2 development.
Camoform works by interacting with a specific molecular target to produce a therapeutic effect.
Camoform, also known as Bialamicol, is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not FDA approved for any indications. The drug's pharmacokinetic properties, including half-life and bioavailability, are also unknown. Camoform is owned by an unspecified company, and its generic status is not confirmed. Further research is needed to understand its clinical applications and safety profile.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BIALAMICOL |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have locks on them, and Camoform is a key that fits into one of those locks. When it binds to the lock, it triggers a series of events that help to treat a particular condition. This is a simplified explanation of how Camoform works at a molecular level.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Camoform CI brief — competitive landscape report
- Camoform updates RSS · CI watch RSS
Frequently asked questions about Camoform
What is Camoform?
How does Camoform work?
What is the generic name of Camoform?
What development phase is Camoform in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing